International forum of allergy & rhinology · 2026
Nasal Tuft Cell Markers Are Predictive of Overall Survival in Sinonasal Neuroendocrine and Sinonasal Undifferentiated Carcinomas.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dioufa Nikolina, Bruneto Ricardo V, Douglas Jennifer E, Adappa Nithin D, Palmer James N, Cohen Noam A, Kohanski Michael A
Аннотация
BACKGROUND: Sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC) are rare aggressive malignancies with no established prognostic markers. Because features of POU2F3+ small cell lung carcinomas have been identified in both tumors, we evaluated immunostaining for POU2F3, a tuft cell transcription factor, and KIT, a tuft-progenitor marker, to determine whether SNECs/SNUCs exhibit a tuft cell lineage.
METHODS: We retrospectively studied patients with rare sinonasal malignancies treated between 2010 and 2025 at the University of Pennsylvania. Archived specimens underwent immunohistochemistry for KIT, POU2F3, SOX9, TRPM5, ASCL1, and IDH2 R172 mutations. Clinical, radiological, and treatment data were collected. Associations with overall survival (OS) and disease-free survival (DFS) were evaluated using Kaplan-Meier and Cox regression analyses.
RESULTS: KIT was expressed in 90.2% of SNECs (N = 11) and 54.6% of SNUCs (N = 11), with the KIT+POU2F3+ phenotype in 72.7% and 18.2%, respectively. KIT/POU2F3 expression correlated with SOX9 and TRPM5, and KIT/POU2F3 phenotypes correlated with IDH2 R172 mutation status (p = 0.015). KIT+POU2F3+ tumors had significantly improved OS (p = 0.004) and DFS (p = 0.001). Univariable analysis showed that lack of double positive KIT/POU2F3 phenotype predicted decreased OS (HR: 12.24; 95% CI: 2.29-226.78; p = 0.001) and DFS (p < 0.001). In multivariable analyses, this association persisted for OS in models including histologic subtype or IDH2 mutation status.
CONCLUSIONS: Results indicate that a subgroup of SNECs and SNUCs expresses a tuft cell-associated marker profile. KIT+POU2F3+ SNECS and SNUCs have markedly improved OS and DFS suggesting these markers have diagnostic, prognostic and potentially therapeutic utility.
METHODS: We retrospectively studied patients with rare sinonasal malignancies treated between 2010 and 2025 at the University of Pennsylvania. Archived specimens underwent immunohistochemistry for KIT, POU2F3, SOX9, TRPM5, ASCL1, and IDH2 R172 mutations. Clinical, radiological, and treatment data were collected. Associations with overall survival (OS) and disease-free survival (DFS) were evaluated using Kaplan-Meier and Cox regression analyses.
RESULTS: KIT was expressed in 90.2% of SNECs (N = 11) and 54.6% of SNUCs (N = 11), with the KIT+POU2F3+ phenotype in 72.7% and 18.2%, respectively. KIT/POU2F3 expression correlated with SOX9 and TRPM5, and KIT/POU2F3 phenotypes correlated with IDH2 R172 mutation status (p = 0.015). KIT+POU2F3+ tumors had significantly improved OS (p = 0.004) and DFS (p = 0.001). Univariable analysis showed that lack of double positive KIT/POU2F3 phenotype predicted decreased OS (HR: 12.24; 95% CI: 2.29-226.78; p = 0.001) and DFS (p < 0.001). In multivariable analyses, this association persisted for OS in models including histologic subtype or IDH2 mutation status.
CONCLUSIONS: Results indicate that a subgroup of SNECs and SNUCs expresses a tuft cell-associated marker profile. KIT+POU2F3+ SNECS and SNUCs have markedly improved OS and DFS suggesting these markers have diagnostic, prognostic and potentially therapeutic utility.